IQVIA Hldgs Option Alert: Dec 19 $180 Puts Sweep (23) near the Bid: 164 vs 146 OI; Earnings 5/6 Before Open 

IQVIA Hldgs Option Alert: Dec 19 $180 Puts Sweep (23) near the Bid: 164 @ $33.4 vs 146 OI; Earnings 5/6 Before Open Ref=$152.05

IQVIA Hldgs (NYSE:IQV) 주식

IQVIA HOLDINGS INC

IQVIA Hldgs

Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Holdings

Nvidia

Analyst Color

Long Ideas

Health Care

Analyst Ratings

Tech

Trading Ideas

General

ILMN

NVDA

엔비디아(NASDAQ:NVDA)의 제품은 GPU와 게임에 국한되지 않는다. 이 기술 회사는 현재 헬스케어 인공지능 분야에서도 주목받고 있다. 월요일에 열린 J.P. 모건의 헬스케어 컨퍼런스에서 애널리스트 할란 서(Harlan Sur)는 엔비디아의 전략적 위치와 향후 성장의 주요 동력을 강조했다. 이것이 월스트리트와 병원들이 주목하고 있는 이유이다.

엔비디아가 의료 AI로 10억 달러의 매출을 겨냥: 다음 성장의 지평으로 거듭날까?

stock chart-1863880_1920-60

News

BILL

ETSY

ICLR

MTCH

SDRL

엘리엇 인베스트먼트 매니지먼트(Elliott Investment Management)는 3분기에 분주했다. 미 증권거래위원회(SEC)에 새로 제출한 13-F에 따르면 이 행동주의 투자자는 여행 및 숙박에 초점을 맞춘 여러 가지 새로운 포지션을 포함하여 여러 가지 포트폴리오 전환을 수행했다.

엘리엇이 3분기에 웨스턴 디지털, 엣시는 추가; 씨드릴, 블랙라인, NRG 에너지는 축소

IQVIA Holdings Inc

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $47 price target.

Price Target

Reiteration

CDTX

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $47 Price Target

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and raises the price target from $26 to $29.

APLS

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Raises Price Target to $29

Wells Fargo analyst Edward Kelly maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Overweight and raises the price target from $90 to $105.

DLTR

Wells Fargo Maintains Overweight on Dollar Tree, Raises Price Target to $105

JMP Securities analyst Mitch Germain reiterates Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) with a Market Outperform and maintains $21 price target.

JMP Securities Reiterates Market Outperform on Broadstone Net Lease, Maintains $21 Price Target

<ul>
<li>Relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection</li>
<li>Addition of relacorilant did not increase side-effects, compared to nab-paclitaxel monotherapy</li>
<li>Results presented in late-breaking podium presentation at ASCO 2025 with simultaneous publication in The Lancet</li>
</ul>
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in a late-breaking oral presentation at the ASCO 2025 (American Society of Clinical Oncology) Annual Meeting.
The presentation abstract can be found <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F243880&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=39fc98b20cea82363bf0c1ee891d18a4">here</a> and the presentation slides <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcorcept.com%2Frosella-data-asco-2025%2F&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=d027378ea105f9965e68b33374254744">here</a>. The data have been simultaneously published in The Lancet, titled "<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252825%252901040-2%2Ffulltext&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=Relacorilant+and+nab-paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer+%28ROSELLA%29%3A+an+open-label%2C+randomised%2C+controlled%2C+phase+3+trial&amp;index=3&amp;md5=9d1728b37a7ce57af0fea2a9f7d8fcd5">Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial</a>."
ROSELLA met its primary endpoint of improved progression-free survival as assessed by blinded independent central review (PFS-BICR). Patients who received relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients who received nab-paclitaxel monotherapy (hazard ratio: 0.70; p-value: 0.0076). Median PFS-BICR was extended to 6.5 months, compared to 5.5 months in patients who received nab-paclitaxel alone. In addition, PFS assessed by investigators was consistent with PFS-BICR, with a hazard ratio of 0.71 (p-value: 0.0030). An interim analysis of overall survival (OS), showed that the addition of relacorilant reduced the risk of death by 31 percent, substantially lengthening patients' lives. Median OS for patients who received relacorilant was 16.0 months, compared to 11.5 months for patients who received nab-paclitaxel alone (hazard ratio: 0.69; p-value: 0.0121). These benefits were seen in all clinically relevant subgroups, including those with poor prognoses.
Relacorilant plus nab-paclitaxel was well-tolerated, with a comparable safety profile between treatment arms. The addition of relacorilant did not increase patients' safety burden. In addition, patients treated with relacorilant plus nab-paclitaxel had a lower incidence of ascites (5.3 percent), than did patients who received nab-paclitaxel alone (10.5 percent). The occurrence of abdominal paracenteses during treatment was also lower for patients treated with relacorilant plus nab-paclitaxel (7.4 percent), compared to nab-paclitaxel alone (13.2 percent).

Biotech

CORT

Corcept Therapeutics Reports Phase 3 ROSELLA Trial Results As Relacorilant Plus Nab-Paclitaxel Improves Survival In Platinum-Resistant Ovarian Cancer Without Added Side Effects, Showing 30% Reduced Progression Risk And 31% Lower Death Risk In ASCO 2025 Late-Breaker And Simultaneous Lancet Publication

Wells Fargo analyst Chris Carey maintains Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Equal-Weight and lowers the price target from $27 to $23.

Wells Fargo Maintains Equal-Weight on Conagra Brands, Lowers Price Target to $23

Wells Fargo analyst Andrew Nowinski maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $430 to $550.

CRWD

Wells Fargo Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $550

Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>), a leading provider of rugged mobile solutions, today announced the signing of a Letter of Intent (LOI) with Social Mobile&#xAE;, a leading provider of enterprise mobility solutions.
<ul>
<li>Pursuant to the LOI, Social Mobile and Sonim intend to enter into a definitive agreement for the potential acquisition by Social Mobile of substantially all of the assets of Sonim and its direct and indirect subsidiaries (the "Transaction"). The LOI contemplates a purchase price of up to $20 million, including up to $5 million in earn-out consideration contingent upon achieving the target revenue as set forth in the LOI.</li>
<li>The LOI contemplates customary working capital and escrow terms.</li>
<li>The LOI grants Social Mobile an exclusivity period to negotiate and consummate the Transaction and permits Sonim to continue evaluating potential reverse take-over transactions (RTO) opportunities.</li>
</ul>
The Special Committee of Sonim's Board of Directors, in consultation with its financial adviser, concluded that the proposed Transaction, if consummated, represents a compelling strategic opportunity to maximize value to Sonim's stockholders while supporting the continued advancement of the Company's innovative technology offerings.
Following an exhaustive review of strategic alternatives, the Special Committee determined that the proposed Transaction with Social Mobile best aligns with its goal of maximizing stockholder value. Key highlights of the LOI include:
<ul>
<li>a clearly defined structure;</li>
<li>secured financing without contingencies; and</li>
<li>an opportunity for Sonim to engage in an RTO.</li>
</ul>
The Transaction is subject to customary closing conditions and approvals.

Contracts

Asset Sales

SONM

Reported Earlier: Sonim Technologies Signs LOI For Potential $20M Asset Sale To Social Mobile, Including $5M Earn-Out

Prominent former Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) employees have shared their experiences during their time with Elon Musk's tech giant amid the CEO&#8217;s commitment to the company.
What Happened: "The success rate of former Tesla employees starting their own companies, building hard things, is exceptionally high," former Tesla Optimus lead Chris Walti said, referring to former senior Tesla team members going on to establish their own companies, in an interview with Business Insider <a href="https://www.businessinsider.com/ex-tesla-founders-what-they-learned-working-elon-musk-2025-5">on</a> Sunday.
Besides Walti, the interview also featured Gene Berdichevsky, who said that the company offers a sense of "radical self-reliance" and an experience unlike a "9-to-5," while Walti hailed the lack of bureaucracy at the company. "You can solve problems without requiring 20 product managers and five VPs for approval," he said.
However, they also acknowledged that working at the company does have its challenges and pressure. "Elon has a short fuse. It doesn&#8217;t matter how many successful projects you&#8217;ve delivered. You screw up once and you might be out.&#8221; Berdichevsky shared.
Why It Matters: The interview comes at a time when Tesla has been grappling with dwindling sales figures as well as prominent analysts and insiders <a href="https://www.benzinga.com/25/05/45660989/cathie-wood-ditches-5-6m-more-tesla-while-elon-musk-quits-government-role-doubles-down-on-ai-stock-under-attack-by-short-sellers">selling their stock positions</a> in the company.&nbsp;
While sales are declining, CEO Elon Musk has shared that the company is targeting a June 12 launch for its highly anticipated Robotaxi in Austin. This coincides with the billionaire announcing his exit from DOGE and his association with the Trump administration at the White House.
Interestingly, Musk has been <a href="https://www.benzinga.com/news/topics/25/05/45708285/elon-musk-lobbies-for-support-from-lawmakers-on-legislation-for-self-driving-cars-report">actively lobbying U.S. lawmakers </a>to revise regulations for autonomous driving in the country. The billionaire and his team have reportedly been in direct contact with Congress members.
This is in line with Musk's comments<a href="https://www.benzinga.com/25/05/45536915/transportation-secretary-sean-duffy-visits-elon-musks-tesla-gigafactory-in-austin-hints-at-possible-federal-autonomous-driving-regulations"> during a meeting </a>with U.S. Transportation Secretary Sean Duffy at Tesla's factory in Texas, where Musk outlined a need for federal regulation for autonomous vehicles.
Price Action: TSLA declined 1.41% in Pre-Market trading, currently valued at $341.56, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45716179/teslas-china-sales-slump-while-byd-and-li-auto-post-strong-gains-report">Tesla&#8217;s China Sales Slump While BYD And Li Auto Post Strong Gains: Report</a></li>
</ul>
Photo: Shutterstock

TSLA

These Former Senior Tesla Employees Share What It Was Like Working With Elon Musk: "It's Not A 9-To-5 Experience…"

WIIM

ACTU

Actuate Therapeutics shares are trading lower. The company announced highlights from its Key Opinion Leader event that discussed topline results from its topline elraglusib phase 2 data in first-line treatment of metastatic pancreatic cancer.

<a href="https://www.bloomberg.com/news/articles/2025-06-02/byron-allen-hires-moelis-to-shop-1-billion-in-local-tv-stations?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-02/byron-allen-hires-moelis-to-shop-1-billion-in-local-tv-stations?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-02/byron-allen-hires-moelis-to-shop-1-billion-in-local-tv-stations?srnd=homepage-americas</a>

'Byron Allen Hires Moelis To Shop $1 Billion In Local TV Stations' - Bloomberg News

First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics
Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible&nbsp;
REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEER#NASDAQ">SEER</a>), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph&#xAE; ONE Assay and SP200 Automation Instrument along with the Thermo Scientific&#x2122; Orbitrap&#x2122; Astral&#x2122; mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes.
Seer's latest platform advances will allow deep, unbiased proteomic analysis of&nbsp;20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research.

SEER

Reported June 1, 2025: Seer And Korea University Launch Large-Scale Study Using Proteograph ONE Assay And Mass Spectrometry To Identify Early-Onset Cancer Biomarkers In Young Adults

Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) has outperformed the market over the past 5 years by 8.34% on an annualized basis producing an average annual return of 21.38%. Currently, Brown &amp; Brown has a market capitalization of $32.26 billion. 
Buying $1000 In BRO: If an investor had bought $1000 of BRO stock 5 years ago, it would be worth $2,677.45 today based on a price of $112.56 for BRO at the time of writing.
<h3>Brown &amp; Brown's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748877311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Brown & Brown 5 Years Ago Would Be Worth This Much Today

UBS analyst Daniel Ford maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Buy and raises the price target from $113 to $114.

UBS Maintains Buy on Ameren, Raises Price Target to $114

45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy
Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4%
Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) (the "Company"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced data in a poster titled, "Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding CAB-ROR2-ADC, in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck." The poster will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois.
In the Phase 2 clinical trial, patients with heavily pretreated squamous cell carcinoma of the head and neck (SCCHN) received 1.8 mg/kg of Oz-V given in two schedules: once every two weeks (Q2W) or days 1 and 8 of a 21-day cycle (2Q3W). Tumor assessments were conducted by CT or MRI every 6 weeks from cycle 1 day 1 until week 12, then every 8 weeks up to one year. Response-evaluable patients included those with at least one post-treatment scan.
HPV associated expression of E6 and/or E7 oncoproteins drives cancer progression by upregulating ROR2 expression, which is expressed at high rates in OPSCC. Thus, there is a compelling rationale to evaluate Oz-V in HPV associated OPSCC patients.

BCAB

Reported Earlier: BioAtla Reports 45% ORR And 100% DCR In Heavily Pretreated HPV+ OPSCC Patients In Phase 2 Trial Of Ozuriftamab Vedotin

UBS analyst Thiago Batista maintains Credicorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAP#NYSE">BAP</a>) with a Buy and raises the price target from $221 to $257.

UBS Maintains Buy on Credicorp, Raises Price Target to $257

UBS analyst Thiago Batista maintains Banco Santander Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSAC#NYSE">BSAC</a>) with a Neutral and raises the price target from $20 to $24.

BSAC

UBS Maintains Neutral on Banco Santander Chile, Raises Price Target to $24

MULN

Mullen Automotive shares are trading lower after the company announced it acquired an additional 21% of Bollinger Motors. The company also completed its reverse stock split.

LOGC

ContextLogic shares are trading lower after the company announced it will delist from the Nasdaq and begin trading on the OTC markets.

Press Releases

IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services

Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards

IQVIA Reports First-Quarter 2025 Results

IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQVIA Announces Offering of Senior Notes

RNTX

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

IQVIA Hldgs

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌